|Bid||44.08 x 1300|
|Ask||44.15 x 4000|
|Day's range||43.88 - 44.39|
|52-week range||41.45 - 56.32|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||8.05|
|Forward dividend & yield||1.64 (3.73%)|
|Ex-dividend date||26 Jan 2023|
|1y target est||N/A|
NEW YORK, January 31, 2023--Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
DAVOS, Switzerland, January 17, 2023--Pfizer Inc. (NYSE: PFE) today announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has global rights on a not-for-profit basis to enable greater health for 1.2 billion people living in 45 lower-income countries.
NEW YORK, January 06, 2023--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine in infants and children 6 weeks through 17 years of age, and for the prevention of ot